Inscripta Acquires Infinome Biosciences and Sestina Bio

Intus Bio Acquires Pattern Genomics

June 28, 2023

Biotechnology

Intus Biosciences (Intus Bio) has acquired Pattern Genomics, integrating Pattern's advanced genomic analysis and machine learning tools into Intus Bio's Titan-1 microbiome assay and analysis platform. The acquisition, supported by investor Connecticut Innovations, brings Pattern Genomics' founder Daniel Fasulo into Intus Bio as Head of IT and Bioinformatics to accelerate capability expansion and biomarker discovery across healthcare and pharmaceutical end markets.

Quintara Biosciences Acquires Laragen Sanger Sequencing Business from Transnetyx

September 15, 2025

Biotechnology

Quintara Biosciences has completed the acquisition of the Laragen Sanger Sequencing business (formerly operated by Transnetyx), effective September 15, 2025. The purchase preserves local operations and customer service in Los Angeles while expanding Quintara’s California sequencing footprint and capabilities.

insitro Acquires Haystack Sciences

October 22, 2020

Biotechnology

insitro has acquired Haystack Sciences to integrate Haystack’s DNA-encoded library (DEL) technology and nDexer platform into insitro’s machine-learning-driven drug discovery efforts. The acquisition expands insitro’s small-molecule design and high-throughput chemistry capabilities to accelerate predictive model-driven therapeutics discovery; financial terms were not disclosed.

Twist Bioscience Acquires iGenomX

June 30, 2021

Biotechnology

Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.

Standard BioTools Acquires Sengenics from Summa Equity

November 21, 2024

Biotechnology

Standard BioTools Inc. has acquired Sengenics Corporation Pte Ltd, a Summa Equity portfolio company, to broaden its proteomics and antibody‑profiling capabilities. The deal will integrate Sengenics' KREX™ immunoproteomics and i-OME™ Discovery platform with Standard BioTools' SomaScan/proteomics offerings to enhance biomarker discovery and accelerate drug development.

Intellia Therapeutics Acquires Rewrite Therapeutics

February 3, 2022

Biotechnology

Intellia Therapeutics has acquired Rewrite Therapeutics, a UC Berkeley–spawned startup developing DNA-writing genome editing technologies. The deal includes $45 million upfront and up to $155 million in research and regulatory milestones, expanding Intellia's in-house editing capabilities to potentially enable new precision editing strategies.